Tumor-associated antigen presentation via dendritic cell activation

Tumor-associated antigen (TAA) presentation via dendritic cell (DC) activation refers to the process by which dendritic cells, as professional antigen-presenting cells (APCs), capture, process, and present antigens derived from tumor cells to T lymphocytes. This mechanism is central to initiating and regulating anti-tumor immune responses, particularly the activation of cytotoxic CD8+ T cells that can recognize and kill tumor cells. Strategies that enhance antigen delivery specifically to activating receptors on dendritic cell surfaces have been explored as cancer vaccines, aiming to boost specific anti-tumor immunity by improving both uptake efficiency and subsequent presentation pathways. Clinical approaches include ex vivo loading/maturation of autologous patient-derived DCs with defined TAAs followed by reinfusion ("DC vaccines"), as well as agents designed to reprogram endogenous dysfunctional intratumoral DC populations toward an immunostimulatory phenotype. In many cancers, intratumoral DC function is suppressed by immunosuppressive factors such as regulatory T-cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), hypoxia, acidic pH, and inhibitory cytokines within the TME, resulting in poor stimulation of anti-tumor immunity and representing a major barrier for effective immune surveillance and therapy response.

Enhancement of antigen presentation by dendritic cells to stimulate T cell-mediated anti-tumor immunity